1. Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network
- Author
-
Segala, Daniela, Barbieri, Marco, Di Nuzzo, Mariachiara, Benazzi, Melissa, Bonazza, Aurora, Romanini, Letizia, Quarta, Brunella, Scolz, Kristian, Marra, Anna, Campioni, Diana, Cultrera, Rosario, Segala, Daniela, Barbieri, Marco, Di Nuzzo, Mariachiara, Benazzi, Melissa, Bonazza, Aurora, Romanini, Letizia, Quarta, Brunella, Scolz, Kristian, Marra, Anna, Campioni, Diana, and Cultrera, Rosario
- Abstract
Introduction: The therapeutic approach to the patient with acute bacterial skin and skin structure infection (ABSSSI) and complicated infections often involves the early transition from intravenous to oral therapy (early switch) or early discharge. Our study aimed to evaluate sustainable and innovative care models that can be transferred to community healthcare and the economic impact of dalbavancin therapy vs Standard of Care (SoC) therapy for the treatment of ABSSSI and other Gram-positive infections including those by multidrug-resistant organisms. We also described the organization of an infectious disease network that allows optimizing the treatment of ABSSSI and other complex infections with dalbavancin. Materials and Methods: We retrospectively studied all patients treated with dalbavancin in the University Hospital “S. Anna” of Ferrara, Italy, between November 2016 and December 2022. The clinical information of each patient was collected from the hospital’s SAP database and used to evaluate the impact of dalbavancin in early discharge with reduction of length of stay promoting dehospitalization and in improving adherence to antibiotic therapy Results: A total of 287 patients (165 males and 122 females) were included in the study of which 62 were treated with dalbavancin. In 13/62 patients dalbavancin was administered in a single dose at the completion of therapy to facilitate early discharge. Assuming a 12-day hospitalization required for the treatment of ABSSSI or to complete the treatment of osteomyelitis or spondilodiscitis, the treatment with dalbavancin results in a cost reduction of more than €3,200 per single patient compared to SoC (dancomycin, linezolid or vancomycin) Conclusions: Dalbavancin has proven to be a valid therapeutic aid in the organization of a territorial infectious disease network given its prolonged action, which allows the dehospitalization with management of even patients with complex infections in outpatient parenteral antimicrobi
- Published
- 2024